According to the Zhitong Finance App, Tailing Pharmaceutical (01011.HK) announced its 2024 interim results. The revenue from continuing operations was 31.297 million yuan, an increase of about 3.25 times over the previous year; net profit of 661,000 yuan, which turned a loss into a profit; and profit of 0.03 points per share.

Zhitongcaijing · 08/30 11:33
According to the Zhitong Finance App, Tailing Pharmaceutical (01011.HK) announced its 2024 interim results. The revenue from continuing operations was 31.297 million yuan, an increase of about 3.25 times over the previous year; net profit of 661,000 yuan, which turned a loss into a profit; and profit of 0.03 points per share.